SML3116
BMS-378806
≥98% (HPLC)
别名:
1-[(2R )-4-Benzoyl-2-methyl-1-piperazinyl]-2-(4-methoxy-1H -pyrrolo[2,3-b ]pyridin-3-yl)-1,2-ethanedione, 4-Benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine, BMS 378806, BMS 806, BMS-806, BMS378806, BMS806
登录查看公司和协议定价
所有图片(1)
About This Item
推荐产品
品質等級
化驗
≥98% (HPLC)
形狀
powder
顏色
white to gray
溶解度
DMSO: 2 mg/mL, clear
儲存溫度
2-8°C
SMILES 字串
O=C(N1[C@@H](CN(CC1)C(C2=CC=CC=C2)=O)C)C(C3=CNC4=NC=CC(OC)=C34)=O
InChI
1S/C22H22N4O4/c1-14-13-25(21(28)15-6-4-3-5-7-15)10-11-26(14)22(29)19(27)16-12-24-20-18(16)17(30-2)8-9-23-20/h3-9,12,14H,10-11,13H2,1-2H3,(H,23,24)/t14-/m1/s1
InChI 密鑰
OKGPFTLYBPQBIX-CQSZACIVSA-N
一般說明
BMS-378806 is an indole-based compound that exhibits improved antiviral potency, and pharmaceutical and pharmacokinetic activities. BMS-378806 is inactive against HIV-2 and Simian immunodeficiency virus (SIV) and a few other viruses.
生化／生理作用
BMS-378806 (BMS-806) is a potent and selective HIV-1 attachment inhibitor that blocks HIV glycoprotein 120 (gp120) from interacting with host T-cell surface glycoprotein CD4 (IC50 = 100 nM against CD4 for binding gp120; CYP1A2/2C9/2C19/2D6/3A4 IC50 >23 μM) without affecting HIV integrase, protease, or reverse transcriptase activity. BMS-806 effectively prevents various HIV-1 isolates from replication (EC50 from 0.85 to 26.5 nM in MT-2 and PM1 cultures; host cytotoxicity IC50 >300 μM) without affecting HIV-2, SIV, MuLV, RSV, HCMV, BVDV, VSV, or influenza virus.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Quantitative determination of BMS-378806 in human plasma and urine by high-performance liquid chromatography/tandem mass spectrometry
Y.-J. Xue, et al.
Journal of Separation Science (2007)
Tao Wang et al.
Journal of medicinal chemistry, 46(20), 4236-4239 (2003-09-19)
Indole derivative 1 interferes with the interaction of the HIV surface protein gp120 with the host cell receptor CD4. The 4-fluoro derivative 2 exhibited markedly enhanced potency and was bioavailable in the rat, dog, and cynomolgus monkey when administered orally
Yuta Hikichi et al.
mBio, 12(1) (2021-01-14)
Despite the effectiveness of antiretroviral (ARV) therapy, virological failure can occur in some HIV-1-infected patients in the absence of mutations in drug target genes. We previously reported that, in vitro, the lab-adapted HIV-1 NL4-3 strain can acquire resistance to the
Shitao Zou et al.
Journal of virology, 94(10) (2020-03-13)
During human immunodeficiency virus type 1 (HIV-1) entry into cells, the viral envelope glycoprotein (Env) trimer [(gp120/gp41)3] binds the receptors CD4 and CCR5 and fuses the viral and cell membranes. CD4 binding changes Env from a pretriggered (state-1) conformation to
Prediction of the binding mode between BMS-378806 and HIV-1 gp120 by docking and molecular dynamics simulation
Ren K, et al.
Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, 766-772 (2006)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门